[Skip to Navigation]
Editor's Note
July 15, 2020

Natriuretic Peptide Levels After Transcatheter Aortic Valve Replacement

Author Affiliations
  • 1Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • 2Editor, JAMA Cardiology
  • 3Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 4Deputy Editor, JAMA Cardiology
JAMA Cardiol. 2020;5(10):1123. doi:10.1001/jamacardio.2020.2623

Among the many measures of the left ventricular response to the pressure overload of severe aortic stenosis (AS) are circulating levels of biomarkers that reflect increases in wall stress, hypertrophy, inflammation, injury, and fibrosis.1,2 The natriuretic peptides have been the most intensively studied in patients with AS. Brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP), ostensibly signals of increased wall stress and myocardial hypertrophy, are elevated in most patients with AS who are symptomatic and may have a potential role in risk stratification of patients with AS without symptoms. Changes in levels of BNP and NT-proBNP in response to aortic valve replacement (AVR), as well as the prognostic implications of persistent elevation of these biomarkers after AVR, have been less well studied.

Add or change institution